Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The new indication is for prevention of sexually transmitted HIV, with the exception of transmission via receptive vaginal sex.
AACR report highlights progress in preventing and treating cancer—including 27 new drug approvals last year—but disparities persist.
Off-label drug use for respiratory infections, asthma or mental health disorders in children is on the rise.
Pretomanid triple therapy cuts the length of treatment from 18 months to six months.
Previously, tests were approved only for use with genital or urine samples.
Eighty percent of medications that receive accelerated approval don’t extend overall survival.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Four out of 10 FDA workers are sidelined.
Did you know there’s a preventive vaccine for the world’s most common STI?
Human papillomavirus vaccine can prevent cervical, anal and oral cancers.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Lucemyra is approved to treat the symptoms of opioid withdrawal for 14 days.
The FDA commissioner wants drugmakers to “end the shenanigans.”
New treatment approaches target tumors with shared characteristics, regardless of where they appear in the body.
Mike Sauers works for the U.S. Food and Drug Administration, and is one of more than 79,000 individuals who make HHS run every day.
Two targeted therapies, Tafinlar and Mekinist, for non-small-cell lung cancer with a specific BRAF mutation have been approved.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.